[e-med] WHO Pharmaceuticals Newsletter No.1, 2005

["Carinne Bruneton" <remed@remed.org>]

Chers amis

La "WHO Pharmaceuticals Newsletter No.1, 2005" est disponible :
http://www.who.int/medicines/library/pnewslet/pn2005_1.pdf

Sommaire

REGULATORY MATTERS

AMIODARONE -- Medication Guide to be dispensed along with medicine
ATOMOXETINE -- Labelling to include liver injury warning
BENZATHINE BENZYLPENICILLIN/ PROCAINE BENZYLPENICILLIN -- Label changes 
highlight appropriate use
MEFLOQUINE -- Patient Information Leaflet to help recognize adverse symptoms
PARACETAMOL-DEXTROPROPOXYPHENE -- To be withdrawn due to risk of toxicity in overdose
SMALLPOX VACCINE -- Label to highlight reports of myopericarditis
THIORIDAZINE -- Withdrawn due to poor benefit/risk profile
SAFETY OF MEDICINES
ATAZANAVIR-RITONAVIR -- Not to be co-administered with omeprazole
CELECOXIB -- Increased risk of cardiovascular events
DARBEPOETIN ALFA -- Adverse outcomes associated with off-label dosing 
strategies
GALANTAMINE -- Ineffective and possibly unsafe in mild cognitive impairment
GLUCOSAMINE -- Concerns about hypercholesterolaemic effects
NAPROXEN -- Long-term study indicates cardiovascular risk
NEVIRAPINE -- Not recommended in women with CD4+ cell counts greater than 
250 cells/mm3
PROPOFOL -- Adverse events with both low- and high-rate infusions
ROSUVASTATIN -- More reports of rhabdomyolysis
DRUGS OF CURRENT INTEREST
Selective Serotonin Reuptake Inhibitors (SSRIs): Potential Adverse Effects
in Neonates -- 'Why reporting matters'
FEATURE
The Indian Pharmacovigilance Programme: a curtain raiser


Carinne Bruneton
Déléguée générale
Réseau Médicaments et Développement (ReMeD)
35 rue Daviel, 75 013 Paris
tél 33 1 53 80 20 20, fax 33 1 53 80 20 21
remed@remed.org ou remed.75013@wandoo.fr
web : http://www.remed.org